Aloradine

Drug Profile

Aloradine

Alternative Names: Aloradine IN; Aloradine NS; PH94B; PH94B NS

Latest Information Update: 03 Dec 2015

Price : $50

At a glance

  • Originator Pherin Pharmaceuticals
  • Class Anxiolytics; Small molecules
  • Mechanism of Action Sensory receptor cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Social phobia

Most Recent Events

  • 18 Feb 2015 Efficacy and adverse events data from a phase III trial in Social phobia released by Pherin Pharmaceuticals
  • 18 Feb 2015 Pherin Pharmaceuticals plans a phase III trial in Social phobia in USA
  • 18 Feb 2015 Pherin Pharmaceuticals has patent protection for Aloradine in USA, Australia, Canada, China, Denmark, France, Germany, Great Britain, Ireland, Italy, Japan, Mexico, Netherlands, South Korea, Spain, Sweden and Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top